Recurrent/Metastatic Gastric Cancer
3
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Trastuzumab Ramucirumab Paclitaxel
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer
Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Research Network
Common Treatments
- Trastuzumab Ramucirumab Paclitaxel1
- M7824paclitaxel1
- Nivolumab Paclitaxel1
Active Sponsors
- Yonsei University3
Top Investigators
Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine
Yonsei Cancer Center, Yonsei University College of Medicine